Licensing and M&A

How accurate are the study costs and assumptions for this licensing deal?  How long will it take bring the compound to market?  When will the key milestones occur?  What kind of resources will we need, and when?  Where are there cost savings opportunities within our collaborative partnering arrangements?

ClearTrial helps you with more informed licensing and M&A activities:

• Generate accurate cost, resource demand, and timeline forecasts for completing clinical development of treatments or portfolio being acquired or licensed, to better gauge fair purchase price/payments
  
  
• Streamline negotiations by leveraging independent, third-party industry metrics for generating resource demand, clinical development cost, and timeline forecasts
  
  
• Rapidly generate accurate “what if” scenarios  (e.g., accelerated development timeline, minimized clinical development cost) to have more options at the negotiating table
  
  
• Quickly roll up costs and resource demand across multiple studies or programs to model economies of scale and risk for in-licensing, out-licensing, M&A, and other collaboration partner arrangements
  
  
• Delineate shared responsibilities, at the task level, and then forecast and allocate the resulting clinical costs when task responsibilities are shared across more than one party
  
  
• Optimize study and portfolio efficiency to maximize margins in collaborative arrangements